1. Home
  2. SWBI vs ACRS Comparison

SWBI vs ACRS Comparison

Compare SWBI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SWBI

Smith & Wesson Brands Inc.

HOLD

Current Price

$15.01

Market Cap

651.8M

Sector

Industrials

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.59

Market Cap

748.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWBI
ACRS
Founded
1852
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
651.8M
748.6M
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
SWBI
ACRS
Price
$15.01
$5.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$14.00
$10.20
AVG Volume (30 Days)
1.0M
2.0M
Earning Date
06-17-2026
05-07-2026
Dividend Yield
3.37%
N/A
EPS Growth
36.67
69.01
EPS
0.41
N/A
Revenue
$523,845,000.00
$1,683,000.00
Revenue This Year
$7.61
N/A
Revenue Next Year
$3.72
$4.24
P/E Ratio
$36.24
N/A
Revenue Growth
10.36
N/A
52 Week Low
$7.73
$1.46
52 Week High
$17.56
$5.85

Technical Indicators

Market Signals
Indicator
SWBI
ACRS
Relative Strength Index (RSI) 46.37 61.86
Support Level $13.83 $4.13
Resistance Level $15.24 $5.85
Average True Range (ATR) 0.47 0.33
MACD -0.07 -0.00
Stochastic Oscillator 13.28 73.40

Price Performance

Historical Comparison
SWBI
ACRS

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: